CJC-1295 No DAC

Overview

CJC-1295 No DAC is a synthetic research peptide that functions as a growth hormone-releasing hormone (GHRH) analog. This version without DAC (Drug Affinity Complex) has a shorter half-life compared to CJC-1295 with DAC but provides a more controlled, pulsatile release of growth hormone in laboratory studies. It is widely studied for its potential to stimulate natural growth hormone secretion in test models such as laboratory rodents.

Benefits

Preclinical research shows that CJC-1295 No DAC may help promote increased growth hormone release, enhanced protein synthesis, and improved recovery in test subjects. Its shorter half-life allows for research focused on mimicking the natural pulsatile secretion of growth hormone rather than continuous exposure.
Source: Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006. Link

Possible Side Effects

In laboratory settings, test subjects administered CJC-1295 No DAC may display mild side effects such as redness or irritation at the injection site, water retention, or slight fluctuations in glucose markers. Effects vary based on dosage, frequency, and species used.
Source: Teichman SL, et al., JCEM, 2006. Link

Dosage & Administration

CJC-1295 No DAC is administered via subcutaneous injection according to approved laboratory protocols. Typical research dosages range from 50 mcg to 200 mcg per injection, with frequency varying from once daily to multiple times per week, depending on study design and species used. It is often paired with a GHRP (Growth Hormone Releasing Peptide) in research to maximize study outcomes.
For laboratory research use only. Not for human consumption.

Summary

CJC-1295 No DAC is a growth hormone-releasing peptide analog designed exclusively for laboratory research on pulsatile GH stimulation, protein synthesis, and recovery pathways in preclinical models. Research indicates it may support natural growth hormone pulses with mild side effects such as injection site redness or water retention noted in test subjects. CJC-1295 No DAC is typically administered via subcutaneous injection, with dosage and frequency adjusted according to study goals.
Strictly for research purposes only. Not for human use.